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Exercise testing is associated with barriers prevent using cardiovascular (CV) endurance (CVE) measure frequently. A recent
nonexercise model (NM) is alleged to estimate CVE without exercise. This study examined CVE relationships, using the NM
model, with measures of obesity, physical ﬁtness (PF), blood glucose and lipid, and circulation in 188 asymptomatic young (18–40
years) adults. Estimated CVE correlated favorably with measures of PF (r = 0.4 − 0.5) including handgrip strength, distance in 6
munities walking test, and shoulder press, and leg extension strengths, obesity (r = 0.2 − 0.7) including % body fat, body water
content, fat mass, muscle mass, BMI, waist and hip circumferences and waist/hip ratio, and circulation (r = 0.2 − 0.3) including
blood pressures, blood ﬂow, vascular resistance, and blood (r = 0.2 − 0.5) proﬁle including glucose, total cholesterol, LDL-C,
HDL-C, and triglycerides. Additionally, diﬀerences (P<0.05) in examined measures were found between the high, average,
and low estimated CVE groups. Obviously the majority of these measures are CV disease risk factors and metabolic syndrome
components. These results enhance the NM scientiﬁc value, and thus, can be further used in clinical and nonclinical settings.
1.Introduction
Diseases of the cardiovascular (CV) system are the number
1 cause of mortality and morbidity in the world and
will continue to be for years to come [1]. Reduced CV
endurance (CVE) increases the risk of hypertension, obesity,
diabetes, and coronary, cerebral, and peripheral vascular
diseases in a variety of populations [2, 3]. Recently, 12.2%
of myocardial [4] and 28.5% of cerebral [5] infarctions
were attributed to lack of physical activities in 2 large-
scale studies involving 74 countries. Additionally, studies
have found that determining CVE can predict all-cause and
CV-related mortality and morbidity in children and young
and older adults with and without CV diseases (CVD).
Therefore, many have recommended to include CVE testing
in the screening for CVDs [6, 7]. However, the risk, time
constrains, inconvenience, and cost associated with exercise
testingpreventfromusingthemaximaloxygenconsumption
(VO2 max)measure,thedirectandgoldenstandardforCVE,
frequently [8, 9].
The previously developed [10] and recently cross-[11]
and criterion- [12] validated nonexercise model (NM) has
been found reasonably accurate to estimate CVE [13].
The model is based on the regression of independent and
objective variables recognized to be related to CVE and
CVD, such as gender, age, body mass index (BMI), resting2 The Scientiﬁc World Journal
heart rate (HR), and self-reported habitual physical activity
(PA) levels. The method is proposed to be a valid and
simple measure of CVE that can be used in clinical setting
without the diﬃculties of exercise testing [13]. However the
relationships of NMVO2 max with CVD risk factors and
metabolic syndrome components have not been examined.
Therefore, the study evaluated the relationships of
NMVO2 m a xw i t hm e a s u r e so fp h y s i c a lﬁ t n e s s( P F ) ,o b e s i t y ,
circulatory, and blood glucose and lipid proﬁle in young
asymptomatic individuals. Given previous ﬁndings [2, 7, 13,
14], these measures are expected to be related to NMVO2
max. Indeed, the majority of these measures are related to
CVD and the metabolic syndrome. These relationships are
particularly important for future clinical and nonclinical
considerations of the model. Especially in the screening for
CVDs asymptomatic individuals can beneﬁt from primary
prevention programs to avoid or at least delay CVDs [15].
2.Methodology
2.1. Participants and Study Design. Asymptomatic appar-
ently healthy males and females between 18 and 40 year
old were invited to participate in this cross-sectional study.
The exclusion criteria were fasting plasma triglycerides ≥
150mg /dL; HDL-C < 40/50mg/dL (men/women); glucose
≥ 110mg/dL; or BP ≥ 130/85mmHg [16]. Additionally,
smokers and individuals with metabolic and CVDs or taking
medications that might aﬀect vascular function, BP, or blood
glucose and lipid proﬁle were excluded from the study.
After a detailed orientation of the experimental procedures,
possible risks, beneﬁts, and requirements, all individuals
signed an informed consent approved by the institutional
review board.
2.2. Health-Related Fitness Measures
2.2.1. Anthropometrics. Body weight (Bweight) in kilo-
grams/the squared height in meters was used to calculate
BMI [17]. Additionally, the participants’ percent body fat
(Fpercent) and body water (Bwater) were measured using
bioelectrical impedance (Microlife WS 100, Microlife AG,
Heerbrugg, Switzerland). Subsequently fat mass (Fmass)
was calculated as Fpercent ∗ Bweight whereas muscle mass
(Mmass) was calculated as the diﬀerence between Bweight
and Fmass [17]. The ratio of the waist and hip (WHR) was
calculated after determining the waist (WC) and hip (HC)
circumferences at the umbilicus height and at the greatest
circumference in the pelvic bone, respectively [17].
2.2.2. Physical Fitness. Handgrip (HGS), shoulders press
(Shpress) and leg extension (Lgext) strengths as well as the 6-
minute walk test (6MWD) were used as measures of physical
ﬁtness. The average HGS was calculated after 3 all-out
griping trials in the dominant hand using a dynamometer
[17]. Each participant walked as fast as possible to examine
themaximumdistanceachievedin6minutes(6MWD)[18].
Shoulder press (Shpress) and leg extension (Lgext) machines
were used to determine upper and lower body strengths,
respectively. The weight-lifted 2–20 repetitions were applied
to the “one repetition maximum (1-RM)” equation to
determine maximal strength. The 1-RM equation = kg at
#RM 2 – 20/[1.00 – (#RM ∗ 0.02)], given that #RM =
number of repetitions performed, 1.00 = 100% as a decimal,
and 0.02 = 2% as a decimal. The 1-RM was then multiplied
by 70% to determine Shpress, and Lgext endurances [17].
2.3. Circulatory Measures
2.3.1. Blood Pressure. Automated noninvasive auscultatory
(Omron HEM-907XL, Omron Healthcare, Inc, Bannock-
burn, Illinois) BP measurements for the systolic (SBP) and
diastolic (DBP) pressures and HR were obtained from the
participantsafter20minutesofsupineresting.Pulsepressure
(PP) was calculated as SBP-DBP whereas mean arterial
pressure (MAP) was calculated as DBP + (1/3∗PP) [17].
2.3.2. Vascular Function. Vascular function measurements
were explained previously in details [19]; however they
will be brieﬂy described. The participants’ blood ﬂows
(BF) at rest (RBF) and after reactive hyperemia (RHBF)
were measured in the dominant forearm with strain-gauge
plethysmography, from a supine position after 20 minutes
resting. Forearm RBF was measured immediately after
releasing a pressure of 7mmHg below DBP applied with
another tourniquet placed above the elbow. The RHBF was
obtained after occluding the upper arm arterial circulation
for 5 minutes. The calculations, for RBF and RHBF, were
made from the slop drawn at the 1st 2-3 beats of the volume
graph. Subsequently, vascular resistance (Vr) at rest (RVr)
and after 5 minutes of upper arm arterial occlusion (RHVr)
was calculated as MAP/Vr [19].
2.4. Glucose and Lipid Proﬁle Measures. Blood samples after
overnight fasting were drawn from each participant by
venipuncture into 5mL plain tubes for serum lipids and
triglycerides determination and into 4mL EDTA containing
tubes for blood glucose and lipid proﬁle (cholesterol,
HDL-C,LDL-C,HDL/LDL,triglyceride)measurements.The
serum was separated from blood cells by centrifugation at
2000 ×gfor10min.Allbiochemicalparameterswereassayed
in the laboratory of King Abdulla University Hospital, Irbid,
Jordan using Roche Chemistry Analyzer andreagents(Roche
Diagnostics, Indianapolis, IN, USA). For all assays, the intra-
assay coeﬃcient of variation was less than 2.6% [20].
2.5. Physical Activity Level. The short-form Arabic version
of the international PA questionnaire (IPAQ) was used to
obtain the level of PA [21]. The subjects were classiﬁed
into low, medium, and high PA levels, according to total
PA participation. The classiﬁcations were according to <600,
601–1500 and >1501, and assigned the values 1, 2, and 3,
respectively [21]. These values were then used in the non
exercise regression equation to estimate VO2 max [10].
2.6. Estimation of VO2 Max Using the Nonexercise Regres-
sion Model. The regression model, originally developed byThe Scientiﬁc World Journal 3
Table 1: Participant characteristics (n = 188).
Variable Mean ± SD Range
Age (years) 24.04 ±5.3 18–40
Weight (kg) 69.7 ±15.8 41–119
Height (cm) 168.6 ±9.5 146–189
Body mass index 24.35 ±4.3 16.5–37.3
Estimated VO2 (mL·kg−1·min−1)4 6 .4 ±6.7 23.1–58.9
Table 2: Estimated maximum VO2 relationship with physical
ﬁtness measures.
Physical ﬁtness measures r value P value
Estimated
VO2 max
Handgrip strength 0.5 0.000
6MWD 0.5 0.000
Leg extension 1RM 0.4 0.000
Shoulder press 1RM 0.5 0.000
Jackson, was used to estimate CVE according to VO2 max
= [Gender(female = 0; male = 1) ∗ 2.77] − [Age ∗ 0.10]
− [BMI ∗ 0.17] − [resting HR ∗ 0.03] + [PA level ∗ 1]
+ 18.07. Subsequently, the participants were classiﬁed into
poor, average, and high level of CVE [10].
2.7. Statistical Analysis. Pearson’s correlations were used
to examine the relationships of NMVO2 max with PF,
circulatory, and blood glucose and lipid proﬁle measures.
Additionally, after dividing the participants into poor, aver-
age, and high CVE groups, 1-way ANOVA tests were used
to examine the diﬀerence between the 3 groups in these
measures.
3. Results
3.1. Participants. As in Table 1, 188 Arab individuals par-
ticipated in the study including 90 males and 98 females
with estimated VO2 max of 51.15 ± 4.6a n d4 2 .0 ±
5.0mL·kg−1·min−1, respectively. The distribution of poor,
average, and high estimated VO2 max groups was 6.4 (n =
12), 55.8 (n = 105), and 37.7% (n = 71), respectively,
with estimated VO2 max 34.1 ± 7.1, 43.9 ± 4.1, and 53.1 ±
4.5mL·kg−1·min−1, respectively. The number of males and
females in the poor, average, and high estimated VO2 max
groups was 1, 36, and 53, and 11, 69, and 18, respectively.
3.2. Estimated VO2 Max Relationships with Health-Related
Fitness Measures. Tables 2 and 3 show that estimated VO2
max correlated with HGS, 6MWD, and Shpress and Lgext
strength and endurance, as well as with Bweight, Fpercent,
Fmass, Bwater, and WHR (r value range: 0.2–0.7). Diﬀer-
ences (P value range: 0.05–0.000) between the 3 groups
in HGS, 6MWD, Spress and Lgext are shown in Table 4.
Similarly, Table 4 demonstrates diﬀerences (P value range:
0.02–0.000)betweenthe3groupsinBweight,BMI,Fpercent,
Fmass, Mmass, Bwater, WC, and HC.
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Figure 1: Estimated VO2 relationship with resting blood ﬂow (a)
(r = 0.3; P = 0.02), resting vascular resistance (b) (r =− 0.2; P =
0.03), and postocclusion blood ﬂow (c) (r = 0.3; P = 0.02).
3.3. Estimated VO2 Max Relationships with Circulatory Mea-
sures . Estimated CVE relationships with BF and Vr are
shown in Figure 1 and with DBP and MAP are shown in
Figures 2 and 3. Additionally, diﬀerences between the 3
groups in RVr (P = 0.05) and RHBF (P = 0.000) are shown
in Figures 4 and 5.
3.4. Estimated VO2 Max Relationships with Blood Glucose
and Lipid Proﬁle. Estimated VO2 correlated favorably with
blood glucose, cholesterol, HDL-C, LDL-C, HDL/LDL, and
triglyceride in the males and females (Table 5) separately
and with cholesterol (Figure 6(a))a n dL D L - C( Figure 6(b))
for the males and females combined. Figure 7 revealed
that blood glucose, cholesterol, and LDL-C were diﬀerent
(P<0.05) between the 3 groups. Table 6 shows that blood4 The Scientiﬁc World Journal
Table 3: Estimated maximum VO2 relationship with body composition measures in the males and females.
Body composition measures Gender r value P value
Weight Males
Females
−0.5
−0.6
0.000
0.000
Body fat percent Males
Females
−0.6
−0.6
0.000
0.000
Body fat mass Males
Females
−0.6
−0.7
0.000
0.000
Estimated
VO2 max Body water content Males
Females
0.3
0.4
0.020
0.006
Waist circumference Males
Females
−0.5
−0.5
0.000
0.000
Hip circumference Males
Females
−0.2
−0.6
0.030
0.000
Waist/hip Males
Females
−0.5
−0.2
0.000
0.040
Table 4: Physical capacity and body composition measures in the high, average, and low estimated VO2 groups.
Measures
Estimated VO2 groups
ANOVA High (n = 71) Average (n = 105) Low (n = 12)
Handgrip strength (kg) 31.9 ±11.12 9 .3 ±13.22 4 .6 ±11.1∗$ 0.020
Maximal walked distance (m) 654.9 ±92.8 579.0 ±82.2$ 517.3 ±65.4∗$ 0.000
Leg extension 1-RM (kg) 41.00 ±18.13 6 .10 ±21.0$ 31.40 ±10.6$ 0.050
Shoulder press 1-RM (kg) 41.60 ±15.33 4 .80 ±17.0$ 30.80 ±9.2$ 0.040
Weight (kg) 67.4 ±13.06 9 .9 ±16.68 2 .2 ±17.6∗$ 0.020
Body mass index 22.2 ±3.22 4 .5 ±4.2$ 30.0 ±4.6∗$ 0.000
Body fat percent (%) 16.7 ±5.82 5 .2 ±6.1$ 32.3 ±5.8∗$ 0.000
Body fat mass (kg) 11.4 ±4.81 8 .0 ±7.0$ 27.0 ±8.5∗$ 0.000
Body muscle mass (kg) 56.2 ±10.75 2 .1 ±12.0$ 55.3 ±11.4 0.040
Water content (kg) 62.0 ±5.65 4 .0 ±3.4$ 54.7 ±3.5$ 0.000
Waist circumference (cm) 78.8 ±10.08 0 .8 ±13.39 0 .7 ±15.1∗$ 0.009
Hip circumference (cm) 99.2 ±7.5 102±10.2$ 111.2 ±9.8∗$ 0.000
Waist/hip 0.8 ±0.07 0.8 ±0.09 0.8 ±0.1 0.620
Values are in mean ± SD. ∗: P<0.05 versus the average; $: P<0.05 versus the high group.
Table 5: Estimated maximum VO2 relationship with blood glucose and lipid proﬁle in the males and females.
Glucose Cholesterol HDL-C LDL-C HDL/LDL Triglyceride
Estimated
VO2
Males −0.04; 0.8 −0.4; 0.01∗ 0.3; 0.03∗ −0.3; 0.02∗ 0.3; 0.03∗ −0.5; 0.002∗
Females −0.4; 0.007∗ −0.3; 0.03∗ 0.1; 0.5 −0.3; 0.03∗ 0.3; 0.05∗ −0.3; 0.03∗
∗: signiﬁcantly correlating with estimated maximal oxygen consumption.
Table 6: Blood glucose and lipid proﬁle for the males in the high and average estimated VO2 groups.
High (n = 53) Average (n = 36) P value
Glucose (mg/dL) 87.7 ±6.88 1 .2 ±11.2 0.200
Cholesterol (mg/dL) 173.3 ±20.6 184.3 ±46.7 0.000
HDL-C (mg/dL) 46.4 ±9.03 4 .1 ±7.1 0.008
LDL-C (mg/dL) 106.1 ±16.3 117.6 ±37.9 0.000
HDL/LDL 0.45 ±0.13 0.32 ±0.14 0.006
Triglyceride (mg/dL) 102.6 ±45.7 158.8 ±88.7 0.025
Values are in mean ± SD.The Scientiﬁc World Journal 5
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Figure 2: Estimated VO2 relationship with DBP in the females (a)
(r =− 0.3; P = 0.005) and males (b) (r =− 0.2; P = 0.03).
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Figure 3: Estimated VO2 relationship with MAP in the females (a)
(r =− 0.2; P = 0.005) and males (b) (r =− 0.2; P = 0.04).
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Figure 4: Resting vascular resistance in the poor, average, and high
estimated VO2 max groups. ∗: P<0.05 versus average and $: P<
0.05 versus high groups.
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Figure 5: Postocclusion blood ﬂow in the poor, average, and high
estimated VO2 max groups. $= P<0.05 versus high groups.
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Figure 6: Estimated VO2 relationship with cholesterol (a) (r =
−0.3; P = 0.001) and LDL-C (b) (r =− 0.3; P = 0.02).6 The Scientiﬁc World Journal
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Figure 7: Blood glucose (a), cholesterol (b), and LDL-C (c) in the
poor, average, and high estimated VO2 max groups. ∗= P<0.05
versus average group; $= P<0.05 versus high group.
cholesterol, HDL-C, LDL-C, HDL/LDL, and triglyceride
among the males were diﬀerent (P<0.05) between the high
and average groups.
4. Discussion
Estimating VO2 max using the regression model was related
to PF, body composition, circulatory, and blood glucose
and lipid proﬁle measures. Additionally, participants in the
higherestimatedVO2 maxcategorywereatlowerriskproﬁle.
Obviously, the majority of these variables are established
CVD risk factors and components of the metabolic syn-
drome. Therefore, these results further enhance the value of
the regression model and thus can be used to estimate CVE
in large-population settings.
Extensive eﬀorts have recently been put forward to iden-
tify asymptomatic persons with or without CV risk factors to
qualify for primary prevention using various diagnostic tools
[8, 22–25]. The diagnostic value of graded exercise testing
(GXT) was recognized some time ago to record changes
in physiological vitals (i.e., HR, BP, and respiratory rate)
for patients with CVDs during maximal exertion [26, 27].
Finding these relationships is quite remarkable, especially
that the participants were young and without CVDs or even
risk factors. These results indicate that NMVO2 max seems
to be useful to diﬀerentiate between individuals according
to CVD risk factor proﬁle and status of the metabolic
syndrome. This is particularly important considering that
previous ample evidences have suggested the possibility
of using CVE testing in risk stratiﬁcation for primary
prevention in asymptomatic individuals [6, 7]. The results
of these studies suggest an independent prognostic and
diagnostic values of maximal exercise capacity (i.e., CVE)
regardless of age, gender, race, and health status [28].
In one of the earliest large-scale studies (>50,000 indi-
viduals) greater CVE was associated with 43 and 53% lower
all-cause mortality, as well as 47 and 70% lower CV-related
mortality in men and women, respectively [29, 30]. More
recently, a meta-analysis for >102,000 individuals concluded
a 13 and 15% lower all-cause and CV-related mortalities,
respectively, with every 1 MET increase in CVE level. The
authorsfurtherelaboratedthata1METincreaseinCVElevel
was comparable to a decrement 7cm in waist circumference,
5mmHg in SBP, 1mmol/L in triglyceride, 1mmol/L in
plasma glucose, and a 0.2mmol/L increment in HDL-C [31].
Assessment of CVE is also valuable and widely used in
quite few nonclinical settings for a variety of purposes. It
can be utilized to predict future performance, is baseline for
exercise prescription, is to evaluate the eﬃciency of exercise
programs, and is helpful for positive motivation [32]. The
relationships of estimated VO2 max with muscle mass, upper
and lower body strength, HGS, and 6MWD measures,
found herein, suggest that NMVO2 max can also be an
acceptable indicator for PF conﬁrming previous ﬁndings
[11–13, 33]. This is vital and indicates that NMVO2 max
might be a simple alternative tool to estimate CVE in young
asymptomatic individuals for nonclinical purposes.
Forearm BF and Vr in the current study are associated
with greater estimated VO2 max in young asymptomatic
individuals conﬁrming the importance of the arterial system
f o rm u s c l eB Ft oa c h i e v eg r e a t e rV O 2 and energy during
maximum performance. Essentially, improved blood deliv-
erytotheworkingmuscleresultsinreducedworkloadplaced
on all components of the CV system at any given intensity,
including resting. This decrease in workload allows the CV
system to function eﬃciently for longer period of time,
delaysfatigue,increasesexercisetolerance,andisessentialfor
healthy CV system [34, 35].
However, despite these compelling evidence conﬁrming
the clinical and nonclinical values of determining CVE
[28–32, 36–39], it is largely underutilized, especially for
CVD risk stratiﬁcation. Rightfully so, one might argue
that lengthy, inconvenient, and risky producers of maximal
exertion during exercise testing might be the reason for notThe Scientiﬁc World Journal 7
using CVE regularly. Alternatively, the current regression
model is claimed to estimate CVE without the “burdens”
associated with “conventional” exercise testing. The research
group, who originally developed the equation, asserts that
themodelisrelativelysimple,low-cost,andlow-riskestimate
of CVE and could be used in clinical, nonclinical, and
research settings. Additionally, the estimation of VO2 max
with the model can serve as a baseline for designing
exercise prescriptions, monitoring adaptations to exercise,
and measuring the success of exercise programming [10,
11, 13]. One slight deviation from the original model is
estimating CVE in the current study with the IPAQ, which
classiﬁes the participants into 3 versus 5 levels used in the
original equation [10, 13]. We think this modiﬁcation can
makethemodelmoreversatileandacceptableinwider-range
settings.
Needless to say, repeatedly challenging the body with
exercise results in adaptations of various body systems to
assure proper energy production during subsequent phys-
ical exertion. Habitual exercise training is associated with
increased CV endurance, HGS, and upper and lower body
strengths. Similarly, overwhelming data demonstrate that
regularparticipation in exercise training results in changes in
body composition measures. Favorable alterations in weight,
abdominal obesity, percent body fat, BMI, and fat-free mass
have been observed even after low-intensity exercise (i.e.,
walking). Though the mechanism(s) for these adaptations
are not entirely known, exercise seems to increase metabolic
rate thereby energy expenditure, even during resting [40–
44]. Changes in blood glucose and lipid proﬁle are also well
established following exercise training, especially aerobic.
Blood glucose, cholesterol, LDL-C, and triglyceride are lower
whereas HDL-C is greater in physically active individuals
[40–44]. Regular exercise also improves muscle blood ﬂow
and VO2 to meet the metabolic demands in subsequent
exercise sessions. The improved blood ﬂow has been
attributed to endothelium-dependent and -independent
structural and functional changes. These changes include
enhanced endothelial [45] and metabolically [46] mediated
vasodilatations, arterial smooth muscle responsiveness [47],
and reduced norepinephrine [48] and endothlin1-mediated
arterial constrictions [49, 50]. Nonetheless, since the CV
system is a continuum, the improvements in the capabilities
of various components directly interact with each other to
enhance O2 delivery to the working muscles [35, 51, 52].
Alterations in blood and stroke volumes, cardiac dimensions
and output, and neurohormonal balance have also been
observed after aerobic exercise [53, 54].
5. Conclusion
Estimation of cardiovascular endurance was related to CVD
risk factors and components of the metabolic syndrome
including measures of obesity, PF, circulatory, and blood
glucose and lipid proﬁle. Thus, the data indicate that the
NM, evaluated herein, can be potentially used as an indirect
measure of VO2 max to screen for CVD risk factors. These
results further enhance the scientiﬁc value of the NM to
be used more in clinical and nonclinical settings. Finally,
the ﬁndings conﬁrm that CVE is useful for weight control,
physical capacity, CV risk factor management and general
CV health.
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